Qlaris Bio is a clinical stage biotechnology company founded with a singular focus: to develop novel, innovative therapies for serious and debilitating ophthalmic diseases.

Qlaris Bio's lead program is QLS-101, a novel compound invented at Mayo Clinic and the University of Minnesota. With QLS-101, we are targeting a key, unaddressed component of intraocular pressure (IOP), Episcleral Venous Pressure (EVP) and outflow distal to the Trabecular Meshwork, that remain wholly unaddressed today. In addition to its potential use alone or as an additive therapy in Primary Open Angle Glaucoma or in Ocular Hypertension, QLS-101 may be able to uniquely address diseases of pathologic EVP and also provide new paradigms of treatment for diseases where EVP sets the floor for maximal IOP lowering therapy, including diseases such as Sturge-weber Syndrome and Normal Tension Glaucoma.

Innovative ocular therapeutics

Innovative ocular therapeutics